MangoGen Pharma Inc. is a privately-owned bio-engineering company with a mission to develop novel gene-delivering medical devices that improve human health. MangoGen, located in Laval, Quebec, Canada, and owns a novel patented technology developed by Prof Satya Prakash at McGill University that utilizes genetically modified baculoviruses that are encapsulated (to protect from serum inactivation) and are coated on to medical devices. On device deployment, the virus enters the local cells, delivers the human gene, and an active protein is expressed. MangoGen’s product pipeline includes the development of gene-delivering coronary stent (the next generation of stents), a gene-delivering film-dressing to promote and accelerate wound healing (e.g. for diabetic foot ulcers), and gene-delivering sutures.
MangoGen was co-founded in 2014 by Professor Satya Prakash, Dr Paul Plested, Dr. Dominique Shum-Tim and Dr Arghya Paul.
MangoGen’s patented technology utilizes a novel approach of using baculovirus encapsulated in a biodegradable coating that is coated onto a coronary stent, or a film-dressing or suture.